Overview

BTRX-246040 Study in Subjects With Parkinson's Disease With Motor Fluctuations

Status:
Completed
Trial end date:
2019-04-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and efficacy of BTRX-246040 in subjects with PD who have motor fluctuations and predictable early morning off periods.
Phase:
Phase 2
Details
Lead Sponsor:
BlackThorn Therapeutics, Inc.